VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LEGNLegend Biotech Corporation
$16.11$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLEGNFinancials

Legend Biotech Corporation (LEGN) Income Statement

9Y historyFree accessUpdated daily

Revenue expanded to $359.5M in 2026Q3 with operating margin turning positive at 13.0%, but gross margin compressed from 73.0% in 2024Q2 to 58.9%, suggesting rising per-patient costs may be absorbing part of the top-line gains.

Income StatementBalance SheetCash FlowRatios

LEGN Income Statement

Annual statement

LEGN Income Statement

Legend Biotech Corporation (LEGN) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Sales/Revenue1.36B1.03B627.24M285.14M117M68.83M75M61.8M49.13M23.59M
Revenue Growth %49.45%64.04%119.97%143.7%70%-8.23%21.36%25.78%108.24%-
Cost of Goods Sold584.36M408.1M234.58M144.21M65.36M0000-96K
COGS % of Revenue-39.66%37.4%50.58%55.86%-----0.41%
Gross Profit774.12M620.8M392.66M140.93M51.64M68.83M75M61.8M49.13M23.69M
Gross Margin %56.98%60.34%62.6%49.42%44.14%100%100%100%100%100.41%
Gross Profit Growth %-58.1%178.62%172.9%-24.97%-8.23%21.36%25.78%107.4%-
Operating Expenses740.02M757.3M695.9M580.41M507.26M461.11M75M194.31M64.2M9.6M
OpEx % of Revenue-73.6%110.95%203.55%433.54%669.97%100%314.42%130.68%40.67%
Selling, General & Admin357.49M341.6M284.26M200.93M174.05M149.5M72.7M32.37M3.93M1.4M
SG&A % of Revenue-33.2%45.32%70.47%148.75%217.22%96.94%52.38%8%5.94%
Research & Development378.58M414.7M413.54M382.22M335.65M313.35M232.16M161.94M60.64M8.2M
R&D % of Revenue-40.31%65.93%134.04%286.87%455.27%309.55%262.04%123.41%34.73%
Other Operating Expenses2M1M-1.91M-2.73M-2.43M-1.74M-229.87M0-2K0
Operating Income34.1M-136.5M-303.24M-439.49M-455.62M-392.29M0-132.51M-1.53M13.78M
Operating Margin %2.51%-13.27%-48.35%-154.13%-389.4%-569.97%--214.42%-3.12%58.41%
Operating Income Growth %-54.99%31%3.54%-16.14%-100%-8538.46%-111.13%-
EBITDA84.37M-107.6M-279.88M-419.03M-437.23M-378.37M-298.16M-127.25M149K14M
EBITDA Margin %6.21%-10.46%-44.62%-146.96%-373.68%-549.75%-397.54%-205.91%0.3%59.33%
EBITDA Growth %150.63%61.56%33.21%4.16%-15.56%-26.9%-134.3%-85504.03%-98.94%-
D&A (Non-Cash Add-back)50.27M28.9M23.36M20.45M18.39M13.92M9.93M5.26M1.68M217K
EBIT49.28M-261.2M-136.52M-498.32M-434.93M-406.3M-308.09M-132.51M-1.53M13.84M
Net Interest Income8.47M18.7M39.59M32.69M-2.61M71K-1.28M4.36M6.13M0
Interest Income23.55M40.1M61.2M54.49M8.18M971K2.93M4.58M6.21M1K
Interest Expense15.08M21.4M21.61M21.79M10.8M900K4.21M223K82K0
Other Income/Expense-1.9M-146.1M145.11M-80.63M9.9M-14.91M-308.29M5.2M13.46M-40K
Pretax Income32.2M-282.6M-158.13M-520.12M-445.72M-407.2M-308.29M-127.32M-1.62M13.84M
Pretax Margin %2.37%-27.47%-25.21%-182.41%-380.94%-591.63%-411.05%-206.02%-3.29%58.65%
Income Tax32.42M14.2M18.89M-1.86M625K-3.61M-41.91M-25.73M1.17M4.47M
Effective Tax Rate %100.67%-5.02%-11.95%0.36%-0.14%0.89%13.6%20.21%-72.28%32.32%
Net Income-215K-296.8M-177.03M-518.25M-446.35M-403.58M-266.37M-101.59M-2.78M9.37M
Net Margin %-0.02%-28.85%-28.22%-181.75%-381.48%-586.38%-355.16%-164.39%-5.67%39.69%
Net Income Growth %99.91%-67.66%65.84%-16.11%-10.6%-51.51%-162.2%-3549.07%-129.73%-
Net Income (Continuing)-215K-296.8M-177.03M-518.25M-446.35M-403.58M-266.37M-101.59M-2.78M9.37M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)-0.00-1.60-0.97-2.94-2.81-2.74-2.57-1.01-0.030.07
EPS Growth %97.71%-64.95%67.01%-4.63%-2.55%-6.61%-154.46%-3533.09%-139.21%-
EPS (Basic)--1.60-0.97-2.94-2.81-2.74-2.57-1.01-0.030.07
Diluted Shares Outstanding193.8M184.32M182.85M176.08M159.04M140.85M118.15M132.01M100.21M132.01M
Basic Shares Outstanding187M184.32M182.85M176.08M159.04M140.85M118.15M132.01M100M132.01M
Dividend Payout Ratio----------

Key Metrics

Growth RegimeExpanding
ProfitabilityWeak
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Persistent operating losses despite growth

Revenue Growth Driven by Carvykti Expansion

Based on reported quarterly figures, LEGN's revenue rose from $160.2M in 2024Q3 to $359.5M in 2026Q3, a year-over-year growth rate of roughly 32% to 70% across recent quarters that suggests the commercial launch is gaining meaningful momentum.

The reported growth trajectory appears driven primarily by expanding Carvykti patient volumes and label expansion into earlier lines of therapy, though the lumpy quarterly pattern suggests milestone timing may be contributing to period-to-period swings. Investors should monitor whether growth remains durable once milestone recognitions normalize, since the sequential decline from $387.5M in 2026Q2 to $359.5M in 2026Q3 may indicate volatility rather than a sustained trend.

Gross Margin Compressed Below Earlier Peaks

According to reported income statements, LEGN's gross margin fell from 73.0% in 2024Q2 to 58.9% in 2026Q3, a decline that may reflect rising per-patient manufacturing and logistics costs as volumes scale.

The compression suggests the individualized autologous manufacturing process carries cost characteristics that do not scale as favorably as small-molecule or software-like economics. Whether margins stabilize near current levels or recover will likely depend on manufacturing efficiency gains, and investors should monitor whether the 2026Q1 trough of 42.3% represents an anomaly or an emerging structural pattern.

Operating Losses Persist Despite Revenue Scale

Based on reported figures, LEGN's operating margin moved from -43.7% in 2024Q3 to a positive 13.0% in 2026Q3, indicating that operating leverage has begun to emerge after several quarters of sustained losses.

The shift to positive operating income in recent quarters suggests that R&D and SG&A spend, while still substantial at roughly $95M and $70M respectively, is being absorbed more efficiently against a growing revenue base. However, the negative operating result in 2026Q1 indicates the improvement has not been linear, so investors should treat the recent positive quarters as early evidence warranting further confirmation.

Net Income Diverges from Operating Results

As reported in financial statements, LEGN's net income swung from -$125.4M in 2025Q2 to $51.7M in 2026Q3, a divergence from operating results that may reflect non-operating items or partnership accounting effects.

The gap between operating income and net income in several quarters suggests non-operating items, tax effects, or collaboration accounting adjustments are materially influencing reported earnings. Given the 50/50 profit-sharing structure with Janssen, analysts should examine whether reported net income reflects distributable economics or accounting timing, and treat EPS figures with caution until this is clarified.

Growth Quality and Cash Burn Risks

Based on reported quarterly data, LEGN recorded net losses in most of the last ten quarters, and the absence of formal guidance in recent reports may limit visibility into whether operating leverage is durable.

A bear case would emphasize that revenue growth is concentrated in a single asset, that gross margins have compressed meaningfully, and that milestone-driven revenue can obscure underlying commercial demand. Investors should monitor whether the recent positive operating quarters persist, as a reversal would suggest the earnings inflection may be less durable than headline growth implies.

LEGN — Frequently Asked Questions

Quick answers to the most common questions about buying LEGN stock.

What was Legend Biotech Corporation's (LEGN) revenue in 2025?

For fiscal year 2025, Legend Biotech Corporation (LEGN) reported total revenue of $1.03B. This represents a 4260.9% increase compared to $23.6M in 2017.

Is Legend Biotech Corporation (LEGN) profitable?

Legend Biotech Corporation (LEGN) reported a net loss of $296.8M for the fiscal year ending 2025.

What is Legend Biotech Corporation's operating profit margin?

Legend Biotech Corporation (LEGN) reported an operating income of $-136.5M, resulting in an operating profit margin of -13.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Legend Biotech Corporation's gross profit and gross margin?

Legend Biotech Corporation (LEGN) generated $620.8M in gross profit for the year, representing a gross profit margin of 60.3%. This demonstrates the company's core pricing power and production efficiency.